The investigational BTK inhibitor tolebrutinib did not lower the risk of confirmed disability progression compared with placebo in people with primary progressive multiple sclerosis (PPMS), failing to meet the main goal and several key secondary goals of the Phase 3 PERSEUS trial. It did, however, show signs of benefit on MRI scans, including fewer new…
Category: Multiple Sclerosis Research
Was the EBV mimicry Idea based on Quicksand?
Tweet A couple of years ago we were awakened to the prospect of EBV being the cause of multiple sclerosis, at least part of the causal route. It was based on two papers one that it was shown that people who develop MS were infected with Epstein Bar Virus before, maybe years, they got MS….
ACTRIMS 2026: Blocking C3 protein seen to ease MS severity in older mice
The complement system — part of the immune system that helps defend against infections — may play a key role in age-related disease progression in multiple sclerosis (MS), according to findings from a mouse study. In fact, blocking a complement protein called C3 reduced disease severity in older mice but not in younger ones, the…
More Than Just the Sniffles: Navigating Colds and Flu with MS
For the average person, catching a cold is a minor inconvenience—a few days of tissues and cough syrup before bouncing back to work. But for those of us living with multiple sclerosis (MS), the narrative is often drastically different. We … Continue reading → Source: blog.mymsaa.org
ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the first in more than 10 years to slow disability…
Antibodies in the brain
Tweet This week I was arguing that PIRA is a terrible concept because a significant element is due to actions outside the CNS…I suggested that most antibody delivered never reach the CNS. To the average of 80Kg volunteers they give 6mg/kg = 480mg (more than any MS antibody except ocrelizumab and 24 times the ofatumumab…
Remembering February Losses
The month of February may be a shorter month, but it has left a few empty places in my heart. Of course, despite a couple of heartbreaking events that occurred during February, a few great things also happened. It is, as we have always heard, that you cannot have sunshine without darkness, and you cannot experience good without the bad. These…
MS: Feeling seen doesn’t always mean feeling heard
Despite this, I often refer to MS as a lonely illness. With a vast array of associated neurological and non-neurological symptoms spread over four different types of MS, it will be exponentially difficult to find someone who has the exact same symptoms with a similarly matching field of outcomes. Source: irelandms.com
Progressive Trials Need to consider Age
Tweet This study indicates that rates of brain atrophy are affected by age and that they should be considered. One thinks that would be wise, but one wonders what this would do to the powering of studies (i.e. how big they have to be to find a difference). Trials are difficult to recruit and take…
MS in older age is more likely to go Progressive
Tweet This morning I woke up like someone has been punching me in the arm all night and guess it is all related to neck problems but it is part of that dropping to bits as you get older thing. Toss on top of this multiple sclerosis and you have a neurodegenerative condition (MS) and…